FOI 7272 - Information regarding Jakavi

Date: 26 April 2022 to 26 April 2025

Q1. Does your trust treat myelofibrosis? If not, which other trust do you refer these patients to?

 

Q2. A) Please provide the total number of patients treated in the last 6 months (or the latest 6 months data you have available) for myelofibrosis (ICD10 code D47.4).

 

  1. b) How many of these patients were above age 65?

 

Q3. How many myelofibrosis patients were treated in the past 6 months with Ruxolitinib?

 

Q4. A) How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

 

  1. b) Of these patients, how many were treated in the past 6 months (or the latest 6 months data you have available) with:

 

 

  • Hydroxyurea

 

  • Fedratinib

 

  • Received No Treatment

 

 

Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis?  If so, can you please provide the name of each trial along with the number of patients taking part.

 

  • Request ID:
    7272
  • Category:
    Patient - Activity Data
  • Response:

    April 2022

    Q1. Does your trust treat myelofibrosis? If not, which other trust do you refer these patients to?

     

    Q2. A) Please provide the total number of patients treated in the last 6 months (or the latest 6 months data you have available) for myelofibrosis (ICD10 code D47.4).

     

    1. b) How many of these patients were above age 65?

     

    Q3. How many myelofibrosis patients were treated in the past 6 months with Ruxolitinib?

     

    Q4. A) How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

     

    1. b) Of these patients, how many were treated in the past 6 months (or the latest 6 months data you have available) with:

     

     

    • Hydroxyurea

     

    • Fedratinib

     

    • Received No Treatment

     

    Medway NHS Foundation Trust regret that we are unable to answer these questions as this data is not collated specifically for patients with myelofibrosis. The Trust’s Pharmacy department can confirm the number of patients who have been supplied the drugs, however, Pharmacy records do not show the indication for the treatment or what the drug was prescribed for, This is for the Reporting Period: 1/10/21 to 31/03/22. Please note If the drug is not listed, it is because it has not been listed.

      

    Drug

    Total Number of Patients

    HYDROXYCARBAMIDE

    81

    HYDROXYCARBAMIDE (SIKLOS)

    6

    HYDROXYCARBAMIDE (XROMI)

    <5

    RUXOLITINIB

    <5

     

     

    Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part. No, we have no trials in Medway NHS Foundation Trust for this diagnosis.